Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

Stock Information for PAVmed Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PAVmed Inc.

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.